An observational study in Bile Duct Neoplasms Malignant, sponsored by The First Hospital of Jilin University. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2025-03-20.
Sponsored by The First Hospital of Jilin University · Observational
The main aim of this observational study is to understand the clinicopathological and prognostic information of IPNB, a rare tumor. The participants have already received treatment during their previous routine medical management and took part in follow - up. We will look into their survival information after previous medical visits and treatment.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's enrollment of 118 is below the median of 204 across 1,683 observational studies indexed under Neoplasms.
Browse Neoplasms studies →The First Hospital of Jilin University is the lead sponsor of 181 studies on the registry; 93 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed with IPNB from eight Chinese hospitals over a 10-year period
Exclusion Criteria:
death
Died of various causes after treatment
Time frame: From January 2014 to June 2024
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The First Hospital of Jilin University